- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Recent advances in the bcr-abl negative chronic myeloproliferative diseases ; volume:4 ; number:1 ; day:11 ; month:10 ; year:2006 ; pages:1-9 ; date:6.2006
Journal of translational medicine ; 4, Heft 1 (11.10.2006), 1-9, 6.2006
- Creator
-
Bennett, Michael
- Contributor
-
Stroncek, David F.
SpringerLink (Online service)
- DOI
-
10.1186/1479-5876-4-41
- URN
-
urn:nbn:de:1111-2016041431370
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bennett, Michael
- Stroncek, David F.
- SpringerLink (Online service)
Other Objects (12)
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Functional analysis of BCR-ABL and JAK2V617F induced target genes in myeloproliferative neoplasms
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Regulation of lipocalin 2 expression and function in BCR-ABL- and JAK2V617F-positive myeloproliferative neoplasms
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Functional analysis of BCR-ABL and JAK2V617F induced target genes in myeloproliferative neoplasms
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Regulation of lipocalin 2 expression and function in BCR-ABL- and JAK2V617F-positive myeloproliferative neoplasms
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia
Expressionshemmung des humanen Onkogens Bcr-Abl durch RNA-Interferenz
Molecular mechanisms in Bcr-Abl positive cells : = Molekulare Mechanismen in Bcr-Abl positiven Zellen
Functional analysis of BCR-ABL and JAK2V617F induced target genes in myeloproliferative neoplasms
Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells
SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment
Bcr-Abl tyrosine kinase inhibitors- current status
BCR/ABL positive thrombocythemia: a diagnostic dilemma
Regulation of lipocalin 2 expression and function in BCR-ABL- and JAK2V617F-positive myeloproliferative neoplasms
Vergleich der Dynamik von BCR-ABL Transkripten und BCR-ABL DNA-Kopienzahlen unter Imatinibtherapie bei der Chronisch Myeloischen Leukämie
The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Oligomerisierungshemmung und Biologie von BCR-ABL und seinen Resistenzmutanten
IGF-IR determines the fates of BCR/ABL leukemia